Podcasts about Hodgkin

In March 2025, Keri Darling fell out of bed and hit her head.  A trip to the doctor revealed a large mass on her pancreas.  After a series of scans, Keri received a phone call at work from a nurse who told her she had cancer; not cancer of the pancreas, but a type of blood cancer, Stage IV follicular non-Hodgkin lymphoma.  She was put on a regimen of chemotherapy, bendamustine, followed by immunotherapy, rituximab.  Keri has achieved survivorship, but each day deals with severe fatigue, which she believes is tied to her chemo regimen.  She still goes in for bimonthly injections of rituximab and says he expects to always be dealing with some level of fatigue.  Nonetheless, she finds the time and energy to help others as a cancer coach.   Two years prior to March 2025, Keri was constantly feeling fatigued.  This was annoying, but she had no idea what was behind her feeling so tired so often.  Then in the middle of the night on a Friday, she got out of bed, fell and hit her head.  She and her husband went to the emergency room.  After some scans, doctors detected a large mass on Keri's pancreas.  She and her husband were terrified that she had pancreatic cancer.  A nurse referred her to an oncologist and a gastroenterologist.    Keri said this wasn't a good time for her to deal with a potential cancer diagnosis.  She was just about to start a new job and the insurance from her previous job was going to lapse in a week.  A nurse urged Keri to get insurance through COBRA, which she did.  Nonetheless, she still had to juggle her health and a new job.    She went to a GI doctor who performed a biopsy.  Keri was at work when she received a call from a nurse telling her she had been diagnosed not with pancreatic cancer, but with Stage IV follicular non-Hodgkin lymphoma.  In terms of treatment, she was given three options and chose a mix of chemotherapy and immunotherapy.  The chemotherapy was bendamustine and the immunotherapy was rituximab.   Keri said she had been prescribed medication to combat the ensuing nausea, but that the toughest part of her chemo regimen was the constant fatigue.  She was also plagued with cognitive issues that resulted in post-its all over her home and a lot of attention paid to the calendar on her phone.   Keri Darling says if she thinks to the time before she started feeling constant fatigue in 2023, and thought of her health as 100 percent, now her health is at around 40 percent.  She says every day she feels fatigued.  It is merely a question of how fatigued she will feel, but she approaches each day as a chance for her health to improve over the previous day.   Additional Resources:   Keri's coaching website:   https://www.nexttogether.co (NOT .com)  

Listen without ads at 8$ a month or up on patreon: www.patreon.com/dopeypodcast SUMMARY This week on Dopey Greatest Hits, Dave officially declares July to be Allman Brothers Month and revisits one of his favorite interviews—with Duane Betts, guitarist, songwriter and son of the legendary Dickey Betts. Before the interview, Dave talks about his lifelong love of “Blue Sky,” reflects on a difficult Patreon Zoom and reminds himself of one of recovery's hardest lessons: restraint of pen and tongue. Papa Smurf contributes an incredible story about selling mushrooms in an Allman Brothers parking lot, getting grabbed by undercover cops and escaping after an oblivious hippie accidentally distracts them. A listener named Jeff also shares a disastrous Phish adventure involving craft beer, moonshine, cocaine, getting lost outside the venue while “Maze” played in the distance, wandering through a locked campground and receiving a possession charge that ultimately introduced him to AA. Then Dave sits down with Duane Betts for an intimate and wide-ranging conversation about growing up inside the Allman Brothers family, touring with his father, living at Cher's Malibu home, learning guitar on the road and finding his own musical identity. Duane opens up about Hodgkin lymphoma, discovering Dilaudid after surgery, the Malibu party scene, Molly, cocaine, crack, black tar heroin and a gram-a-day opiate habit. He recalls smoking heroin-and-cocaine speedballs, flipping a car after scoring drugs, waking up beside a friend who had overdosed and nearly dying after a massive cocaine hit. He also describes arrests, drug court, treatment, Suboxone, relapse, touring with Dawes and eventually finding lasting recovery. Now more than seven years sober, Duane talks about meeting his wife in Jackson Hole, staying grounded through music, hiking, yoga and connection, and continuing the Allman Brothers legacy through his solo work, Palmetto Motel and the Allman Betts Family Revival. It is a story about rock-and-roll history, inherited addiction, devastating loss, recovery and finding a life filled with music, gratitude and purpose. Allman Brothers month continues!   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's Tuesday, July 14th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Kevin Swanson, Timothy Reed and Adam McManus Fulani Muslim militia most deadly force against Christians The Observatory for Religious Freedom in Africa has issued a study on terror-related violence on the Dark Continent. The group revealed that the Fulani Muslim militia is by far the most deadly force in the persecution of Christians worldwide. They kill Christians at a rate 4.4 times that of other Muslims. Thus far, they have killed 79,323 people in six years — amounting to 36 people a day. They kill at 3 times the rate of Boko Haram. That's twenty times the number of people that have been killed in the US-Iran war this year.  Senegal, Africa: Marriage is between one man and one woman The National Assembly of the West African country of Senegal has defined marriage as a union between one man and one woman. Homosexuality is still legal in 21 out of 54 African countries. So far, homosexual faux marriage has been incorporated in one nation -- South Africa. U.S.-Iran war is back on America's war with Iran is back on, and the Middle East is in flames.   The U.S. military bombed dozens of military targets yesterday. The Saudis also bombed the Yemen airport. The Houthi-controlled Yemeni government is an ally with Iran in the present war. The Center for Strategic and International Studies reports a depletion of one-third to one-half of American Patriot, Tomahawk, and Terminal High Altitude Areas Defense missiles. At current rates, the replenishment will take four years. This does not include the use of missiles during the period of May through July.  Trump Meme coin tanked; Bitcoin down by 50% The Trump Meme coin has tanked — costing investors $3.8 billion. The president received $636 million from the venture, according to a recent financial disclosure.  However, Bitcoin has also lost half its value since the Trump election in November 2024. Total losses are running about $2.2 trillion for investors. Gold capitalization has increased about 3% since November 2025. 122,000 American layoffs The website Layoffs.fyi records 122,000 layoffs this year. That's the highest rate in four years.  Amazon is leading the pack for corporate layoffs with a total of 30,000 layoffs over the last nine months. America produces more oil than Saudi Arabia and Russia America is now, by far, the largest oil producer in the world — now producing 42% more than Saudi Arabia, and 37% more than Russia. Back in 2008, the United States produced about half of what Saudi Arabia and Russia produced. That has changed dramatically in the last 17 years.  GOP Senator Mitch McConnell rejects rumors he's braindead Republican Senator Mitch McConnell of Kentucky broke the silence and intrigue surrounding his lengthy hospital stay. Rumors had swirled that the senator was braindead or under cardiac arrest after he was transferred to the hospital. The senator has clarified that he had suffered a fall, but he did not break bones or suffer a concussion. Senator Lindsey Graham met his maker Longtime Republican Senator Lindsey Graham of South Carolina went to meet his Maker on Saturday night. According to the D.C. office of the Chief Medical Examiner, Graham died of a ruptured aorta brought on by chronic heart disease. Graham, age 71, was never married and never had children. SC Gov appointed Lindsey Graham's sister to serve remainder of term South Carolina Republican Governor Henry McMaster announced Monday that he has appointed the late Senator's sister, Darline Graham Nordone, to serve the remainder of his term. When Lindsey Graham was 20, his mother died of Hodgkin's lymphoma at age 50, and his father died 15 months later of a heart attack at age 68. Because his sister, then 13 years old, was left orphaned, the service allowed Graham to attend the University of South Carolina in Columbia so he could remain near home as his sister's legal guardian. Here's a portion of Governor McMaster's press conference. McMASTER: “Today, under the law, it's my duty and honor to name someone to serve in the place this extraordinary man for the remainder of his term. “Lindsey took care of his little sister in years long departed. It's my honor to ask his little sister, Darlene Graham, to finish his work for him now. “And by the way, Darlene, I don't know if I told you, but after we spoke on the phone in the wee hours of Sunday morning, and you agreed to serve, through tears. Earlier, I had wondered what you would say, and I was humbled by your quickness to see the duty that you had to serve. “I called the president afterwards, and he thought it was a great idea, and I'm sure that everyone here does as well.” Obamacare premiums going higher Obamacare premiums are jacking up another 14% for next year.   That follows a 20% increase last year. The Peterson-KFF organization notes that the program lost three million members so far this year — now at a total of 19.2 million enrollments.  The average family of four pays $24,000 into Obamacare for this year, and $27,000 next year.  That compares to Samaritan Ministries Christian medical sharing that runs about $8,000 per year.  Hospitals treated COVID-shot rejectors as “plagued rats” Psalm 146:3 instructs us: “to not put your trust in princes, nor in a son of man, in whom there is no help.” Recent Centers for Disease Control numbers indicate that 80% of Americans got at least one COVID shot. U.S. death rates, based on 2019 numbers, rose 17% in 2020 during the COVID crisis. After the vaccine came out in early 2021, the death rate increased again by 23% over 2019 levels. Then, the death rate increased by 16% in 2022. Death rates did not reduce to 2019 levels until 2024. Last year's death rate actually registered 4% less than 2019. Former trauma surgeon Dr. James Miller told podcast host Alix Mayer that those who did not take the Covid shot, after its rollout, were treated differently in hospitals, and in an inhumane manner, like “plagued rats.” Listen. MILLER: “Absolutely, the vaccinated and unvaccinated were treated differently. They started just denying basic health services to unvaccinated people, which spurned not giving diabetes medicine [and] you can't go see your family doctor. "Now, you could still get emergency care in the ER, but 100% you were treated differently. You were treated as a dirty, plagued rat. And this was common in social media. But it was no different in the hospital. The medical community is no different.” Next, Dr. Miller spoke of The Overton Window referring to the moment when an argument becomes politically acceptable to the mainstream population. In this case, it is more acceptable now, in 2026, for Americans to express their distrust of the medical establishment about how it handled the COVID shot rollout and how it mistreated the unvaccinated 20% of the population. The term, The Overton Window, is named after the American policy analyst Joseph Overton. Listen. MILLER: “I think part of why this is such a good time to talk about this is I think The Overton Window has shifted on the discussion. I think all people have realized the medical care system did not meet their expectations during COVID. “I think most people thought, before COVID, when you go to the doctor, they're going to help you out a bit, and you're going to get better, and they're going to wish you well. I think most people thought when I'm really sick, I'm going to go to the hospital and they're gonna help me out a lot and do their best and get me well. “After COVID, most people realized their doctors were there for themselves. Their doctors were more than happy to give them a toxic substance that would hurt them, like the COVID injection. And I think most people came to see that the hospitals were really killing fields.” 28 Georgia inmates got baptized after Bible studies The Grady County, Georgia Sheriff's department issued an official announcement over the weekend: 28 inmates got baptized! They had been faithfully attending Bible studies throughout the week, and confessed their faith in Christ.   The announcement said, “Together, we gathered in prayer, lifted our voices in worship, and celebrated these life-changing decisions. Moments like these serve as a reminder that hope, grace, and redemption are possible for everyone.” Back in March, another 14 inmates were baptized at a Franklin County jailhouse in Florida, according to Channel 7 News. PASTOR: “I'm going to baptize you in the name of the Father and of the Son and of the Holy Spirit. And I'm baptizing you in the power of that cross I'm talking about today. All right, ready?” These inmates also attended Bible studies each week and heard sermons from local pastors. Inmate Ethan Vonier became a Christian behind bars. VONIER: “I found Christ in jail. I feel like the good Lord put me here. We're all doing better each day.” And inmate Robert Hill was grateful for a fresh start and a Biblical destiny. HILL: “It's a new beginning. Everybody in here probably wants a new beginning. You know, he gives it to you. You know what I mean? Gives you a fresh start.  Jeremiah 29:11 -- He has a plan for me. I know it. I want it. I'm going to get it.” Psalm 107:10-14 tells the story: “Those who sat in darkness and in the shadow of death, bound in affliction and irons—because they rebelled against the words of God, and despised the counsel of the Most High. Therefore, He brought down their heart with labor. They fell down, and there was none to help. Then, they cried out to the Lord in their trouble and He saved them out of their distresses. He brought them out of darkness and the shadow of death, and broke their chains in pieces.” Worldview listeners weigh in from Virginia and Texas Joseph Holt, age 20, at Liberty University in Lynchburg, Virginia, wrote me to say, “Thanks for faithfully presenting the news every morning. I like your podcast because it's short and concise. I can get a briefing on the news while I'm brushing my teeth in the morning before work or school starts. You present the facts from a Biblical worldview and do not shrink from condemning evil. Thanks for keeping this up so long. Here's to another great year!” And Richard Powell in Lonetta, Texas wrote, “I appreciate how much time you guys save me by putting the newscast together so I don't have to filter through so much.  I also appreciate that it's concise and that you come from a Biblical perspective.  I typically read it as part of my morning routine.” 8 Worldview listeners gave $2,760 And finally, on Monday by 8:00pm Central, 8 Worldview listeners had stepped up to the plate and invested their treasure to fund the six-member team behind The Worldview for another year Our thanks to Sarina in Barnwell, Alberta, Canada who gave $25, Janna in Midvale, Idaho who gave $75, and Susan in Timnath, Colorado who gave $100. We were touched by the generosity of Bianca in Manzini, Eswatini, Africa who pledged $15/month for 12 months for a total gift of $180. Since their money is worth one-sixteenth what ours is worth, it's like Bianca donated $2,965. Imagine that! And we're grateful to God for Dwayne and Anita in Moriarty, New Mexico who gave $200, Frances in Beacon, New York who pledged $40/month for 12 months for a gift of $480, Stuart in Zillah, Washington who gave $500, and Tim in Blooming Grove, Texas who pledged $100/month for a total gift of $1,200. Those 8 gifts add up to $2,760. Ready for our new grand total? Drum roll please. (drum roll sound effect) $23,803 (sound effect of people cheering) That means we need to raise $32,762 to hit our $56,565 goal by this Friday, July 17th.   We need to find 8 Worldview listeners, just like Tim did, who will pledge $100/month for 12 months, or give a one-time gift of $1,200, 19 folks who will pledge $50/month or give a one-time gift of $600 and 38 listeners who will pledge $25/month or give a one-time gift of $300. Go to TheWorldview.com, click on Give, select the dollar amount, and make sure to click on the “recurring” button if that's your wish.  If Bianca from Eswatini, Africa can give the equivalent of $2,965, what could you give? Go to TheWorldview.com and click on Give. Close And that's The Worldview on this Tuesday, July 14th, in the year of our Lord 2026. Subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  Plus, you can get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

When Dr. Timothy Blain opened his direct primary care practice in the middle of COVID, he finally felt like a “real doctor” again — after two decades of employed medicine, five-year burnout cycles, and the constant ache of knowing he could help patients but never had the time.In this honest and moving episode, Dr. Blain shares his full journey: graduating in 2000 as hospitals bought up practices, surviving non-Hodgkin lymphoma at 38, then weathering COVID pneumonia, a heart attack, and adult-onset Still's disease — all while continuing to care for his patients. He opens up about how DPC helped save his marriage, why empathy is the first thing burnout takes from physicians, and what it truly means to be the patient when you're also the doctor.Dr. Concepcion and Dr. Blain dig into:•The 5-year burnout curve, and why “just take a half day” never works•Building patient loyalty so deep that almost no one left, even through his hospitalizations•Practical steps for leaving employed medicine for DPC (including the prepay discount that funded his startup)•Why DPC doctors may be best positioned to use AI in medicine•Supplements, home visits, ultrasound, and staying curious as a physician•How and why he chose to close his practice — the taxes, timing, and grief involved•Redefining “failure” and finding peace in a one-year sabbaticalWhether you're burned out and dreaming of a way out, a few years into your own DPC, or simply wondering what a fulfilling end to a medical career can look like, this conversation is a breath of fresh air.“Failure is in the eye of the beholder.” — Dr. Timothy Blain—

Broadcast from KSQD, Santa Cruz on 7-09-2026: Researchers refined a technique to reverse skin cell aging by about 30 years while preserving cellular identity. Exposing adult fibroblasts to Yamanaka factors—stopping before full reversion to pluripotent stem cells,reset the epigenetic clock and gene expression patterns to resemble much younger cells. The rejuvenated fibroblasts produced significantly more collagen, migrated faster to close artificial wounds, and showed reversal of gene expression patterns associated with Alzheimer's and cataracts. Since long-term epidemiologic data doesn't yet exist, Dr. Dawn follows up on last week's vaping question by exploring cancer mechanisms. Vaping aerosols impair DNA repair fidelity while triggering IL-6, IL-8, and TNF-alpha secretion. Nicotine-derived nitrosamines, reactive carbonyls (formaldehyde, acetaldehyde, acrolein) are generated when propylene glycol and vegetable glycerin are heated. Upregulated cytochrome P450 enzymes convert precarcinogens like benzopyrene into carcinogens. Mice exposed for 54 weeks developed lung adenocarcinomas in 22% and precancerous bladder hyperplasia in 57%, with markers matching those show predict lung cancer years before diagnosis. The Mexican Biobank—which includes over 40,000 samples from all 31 Mexican states revealed dramatic regional variation in drug-metabolism genes driven by Indigenous ancestry. In Chiapas, nearly 40% of the population carries two copies of a CYP2D6 variant reducing fentanyl metabolism, versus just 10% in Sinaloa. The SLCO1B1 variant hindering statin metabolism is found in over 15% of Yucatán residents., where 8 million Mexicans take statins. Dr. Dawn discusses both the promise and potential dark side of population genetic testing, including UK plans to genotype all children at birth for inborn errors of metabolism. Dr. Dawn briefly revisits the recent Indian study showing conch-shell blowing reduces sleep apnea by 34%, comparing it to earlier didgeridoo research, both of which strengthen airway muscles through forced-blowing exercises. A caller from Capitola recovering from non-Hodgkin's lymphoma near the L5 nerve asks about Japanese Kampo medicine formulas (Goshajinkigan, Yokukansan) for post-treatment nerve pain. Dr. Dawn suggests the pain likely originates from scar tissue tethering the nerve, and recommends consulting the Oriental Medicine Doctor program at Five Branches in Santa Cruz where faculty can advise on herbal formulas that trace back thousands of years through cultural exchange between China and Japan. Dr. Dawn explains Lp(a):lipoprotein(a), a small protein string attached to LDL particles that promotes clumping and clotting, is a genetically-determined coronary artery disease and stroke risk factor invisible to standard lipid panels. Levels of 250 particles double coronary risk and 350 particles triple it. Less than 75 is normal. Two new pharmaceutical strategies are in development to reduce Lp(a) : antisense oligonucleotides (single-stranded RNA that recruits RNase H to cleave target mRNA) and small interfering RNA (double-stranded RNA that triggers destruction of matching mRNA). Pelacarsen, a monthly injection in Phase 3 trials, reduces Lp(a) by 80%. These gene-silencing platforms open therapeutic possibilities for previously undruggable orphan diseases. Vitamin K2 is produced in the gut microbiome. MK-4 is most common in humans. Dr. Dawn recommends MK7 for stabilizing coronary calcium plaques and directing calcium into bone. A study of hepatitis B and C patients found MK4 to be protective in hepatocellular carcinoma. HCC developed in 2 of 21 MK-4-treated patients versus 9 of 19 controls, with a risk ratio of 0.2. MK-4 activates protein kinase A in vitro, inhibits HCC invasiveness, and restores apoptosis signaling that cancer cells normally block. Dr. Dawn recommends a couple milligrams of MK-4 daily for anyone with cirrhosis or prior hepatitis B or C infection.

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for untreated classical Hodgkin lymphoma.

After earning her first-class degree in chemistry from Oxford, Dorothy embarked on an impressive career in the new field of X-ray crystallography. She would ultimately earn many, many accolades for her work. Research: "Dorothy Crowfoot Hodgkin." Encyclopedia of World Biography Online, Gale, 1998. Gale In Context: Opposing Viewpoints, Biophysical Society. “Profiles in Biophysics: Dorothy Hodgkin.” 2016. https://www.biophysics.org/profiles/dorothy-hodgkin Boon, Rachel. “Curator Rachel Boon celebrates the work of Dorothy Hodgkin.” Science Museum. 12/10/2014. https://blog.sciencemuseum.org.uk/celebrating-dorothy-hodgkin-britains-first-female-winner-of-a-nobel-science-prize/ Bragg, Sir William. “Concerning The Nature Of Things.” London. Bell & Sons. 1932. https://archive.org/details/in.ernet.dli.2015.222386/ Bud, Robert. "Discoverers and developers of penicillin (act. 1928–1950)." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-97279 Dodson, Guy. “Dorothy Mary Crowfoot Hodgkin, O.M. 12 May 1910--29 July 1994.” Biographical Memoirs of Fellows of the Royal Society , Dec., 2002, Vol. 48 (Dec., 2002). Via JSTOR. https://www.jstor.org/stable/3650256 DOROTHY CROWFOOT HODGKIN. NobelPrize.org. Nobel Prize Outreach 2026. Wed. 24 Jun 2026. https://www.nobelprize.org/stories/women-who-changed-science/dorothy-hodgkin/ Ferry, Georgina. "Dorothy Hodgkin". Encyclopedia Britannica, 8 May. 2026, https://www.britannica.com/biography/Dorothy-Hodgkin. Accessed 24 June 2026. Ferry, Georgina. "Hodgkin, Dorothy Mary Crowfoot (1910–1994), chemist and crystallographer." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-55028 Ferry, Georgina. “Dorothy Hodgkin: A Life.” Bloomsbury. 1998, 2014. Ferry, Georgina. “Dorothy Hodgkin: on proteins and patterns.” The Lancet, 384, 1496-1497. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61912-7/fulltext Ferry, Georgina. “The making of an exceptional scientist.” Nature. Vol. 464. April 29, 2010. Gamble, Jessa. “When Hodgkin met Thatcher.” Nature. Vol. 514. October 16, 2014. Hodgkin, Dorothy Crowfoot. “The X-ray analysis of complicated molecules.” Nobel Lecture, December 11, 1964. https://www.nobelprize.org/uploads/2018/06/hodgkin-lecture-1.pdf Hodgkin, Dorothy. “The Pugwash Movement.” India International Centre Quarterly. Vol. 13, No. 2. June 1986. Via JSTOR. https://www.jstor.org/stable/23001474 Howard, Judith A.K. “Dorothy Hodgkin and her contributions to biochemistry.” Nature Reviews. Vol. 4. November 2003. gale.com/apps/doc/K1631003072/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=8d7c4045. Accessed 23 June 2026. Pearce, JMS. “Dorothy Crowfoot Hodgkin OM, FRS (1910-1994).” Hektoen International. https://hekint.org/2020/11/04/dorothy-crowfoot-hodgkin-om-frs-1910-1994/ Perutz, Max. “Dorothy Crowfoot ” The Independent. Via The Crystallographic Community. https://www.iucr.org/people/crystallographers/dorothy-crowfoot-hodgkin-by-m.f.-perutz Pietzsch, Jochim. “Perspectives: Enhancing X-ray vision.” Nobel Prize. https://www.nobelprize.org/prizes/chemistry/1964/perspectives/ Ramaseshan, S. “Dorothy Hodgkin and the Indian Connection.” Notes and Records of the Royal Society of London , Jan., 1996. http://www.jstor.com/stable/531845 Root-Bernstein, Robert. “Dorothy Crowfoot Hodgkin: Structure as Art.” Leonardo , 2007, Vol. 40, No. 3 (2007). Via JSTOR. https://www.jstor.org/stable/20206415 Science History Institute Museum and Library. “Dorothy Crowfoot Hodgkin.” https://www.sciencehistory.org/education/scientific-biographies/dorothy-crowfoot-hodgkin/ The Royal Society. “Dorothy Hodgkin FRS.” https://royalsociety.org/about-us/who-we-are/diversity-inclusion/case-studies/scientists-with-disabilities/dorothy-hodgkin/ “Science for peace Building cultures of cooperation and non-violence through scientific collaboration.” 2025. Via JSTOR. https://www.jstor.org/stable/resrep73183.6 University of Oxford History of Science Museum. “Modelling the Structure of Penicillin.” https://www.mhs.ox.ac.uk/backfromthedead/exhibition/the-structure-of-penicillin/index.html Vijayan, M. “An outstanding scientist and great humanist: An obituary of Dorothy Crowfoot Hodgkin.” Current Science, 10 August 1994, Vol. 67, No. 3 (10 August 1994). Via JSTOR. https://www.jstor.org/stable/24095820 Wallace, Rob. “Dorothy Crowfoot Hodgkin: Captured by Crystals.” National World War II 3/16/2022. https://www.nationalww2museum.org/war/articles/dorothy-hodgkin-penicillin-insulin See omnystudio.com/listener for privacy information.

This Day in Legal History: Vermont Bans SlaveryOn July 8, 1777, delegates meeting in Windsor adopted the Constitution of the Vermont Republic—and in doing so, Vermont became the first place in North America to write the prohibition of slavery into its founding law. At a moment when the newly declared United States tolerated and protected human bondage, a small, unrecognized republic on the frontier put a very different principle on paper.The relevant language was striking for its era. The Vermont constitution declared that all people are born equally free and independent, and it provided that no adult could be held as a servant, slave, or apprentice against their will—specifically, no man over twenty-one and no woman over eighteen. It was not a complete abolition; the age limits meant the document did not immediately free everyone, and enforcement in practice was uneven and incomplete for years afterward. But as a matter of constitutional text, it was the first time on this continent that a government's foundational law declared slavery inconsistent with the very idea of being born free.The context matters. In 1777, Vermont was not yet a state—it wouldn't join the Union until 1791—and it existed in a kind of legal limbo, claimed by both New York and New Hampshire and recognized by neither. That outsider status may have given its drafters room to be bolder than their contemporaries. While the framers of the national government were negotiating the compromises that would embed slavery in American law for another four generations—the three-fifths clause, the fugitive slave clause, the twenty-year protection of the slave trade—Vermont's drafters wrote the opposite conviction into their first article.The significance of July 8, 1777 is partly symbolic and partly practical. Symbolically, it established that abolition was not some later invention imposed on a reluctant founding generation, but a principle that existed at the founding itself, chosen by people who could see the contradiction between declaring all men free and holding some in bondage. Practically, Vermont's provision became an early data point in the long argument that would run through the Northwest Ordinance, the gradual emancipation statutes of the northern states, the abolitionist movement, the Civil War, and finally the Thirteenth Amendment. It's a reminder that constitutional law is not just handed down from the most powerful actors—that sometimes the boldest legal principles come from the margins, from a place that wasn't even sure it counted as a state, writing down what it believed the law ought to be.A former Milwaukee County judge, Hannah Dugan, has been sentenced in federal court after being convicted of obstructing an immigration arrest outside her courtroom—a case that became a flashpoint in the fight over the Trump administration's use of courthouses to stage immigration enforcement. Dugan, who is 67 and was an elected circuit court judge, was found guilty of obstructing a federal proceeding, though a jury acquitted her of a lesser concealment charge.Federal immigration agents came to Dugan's courthouse to arrest Eduardo Flores-Ruiz, a Mexican man who was scheduled to appear before her on misdemeanor assault charges. Prosecutors said Dugan directed him out through a non-public “jury door” in an effort to help him avoid the agents waiting in the public hallway. It didn't work—Flores-Ruiz walked through a public hallway with his attorney anyway, and agents arrested him outside after a brief foot chase. But the government charged Dugan criminally for what she did inside the courthouse, and a federal jury convicted her in December.Think about the competing principles colliding here. On one side is the idea that no one, not even a judge, gets to physically obstruct federal law enforcement carrying out its duties. On the other is a real institutional worry that animated a lot of the coverage: if immigration agents stake out courthouses, people with pending cases—victims, witnesses, defendants—may stop showing up at all, which grinds the ordinary work of the state courts to a halt. Dugan's defenders framed her actions as protecting the functioning of her courtroom; prosecutors framed them as obstruction of a federal operation. The jury sided with the government on the core charge.At sentencing, the two sides were far apart. Federal prosecutors declined to recommend a specific term but argued the guidelines called for fifteen to twenty-one months in prison. Dugan's lawyers disputed that calculation and asked U.S. District Judge Lynn Adelman for time served—no prison at all. The significance of the case goes well beyond one judge. It's a marker of how aggressively the administration is willing to pursue anyone perceived to interfere with immigration enforcement, up to and including a sitting judge, and it sends a message to state and local officials everywhere about the personal legal risk of getting between federal agents and their targets.Ex-Wisconsin judge to be sentenced for obstructing immigration arrest | ReutersBayer is moving to bring an end to the sprawling federal litigation over its Roundup weedkiller, following a significant win at the Supreme Court. Late last month, the Court ruled 7-2 in Bayer's favor, and the company is now trying to convert that decision into the dismissal of the failure-to-warn claims that have driven nearly a decade of lawsuits.Thousands of plaintiffs have sued Bayer alleging that Roundup, and specifically its active ingredient glyphosate, caused their non-Hodgkin lymphoma, and that the company violated state law by failing to warn them of that cancer risk. Bayer's winning argument was about federal preemption—the principle that when federal and state law conflict, federal law wins. Bayer argued that because the Environmental Protection Agency has concluded glyphosate poses no cancer risk and requires no cancer warning on the label, plaintiffs can't use state failure-to-warn law to demand a warning the federal regulator affirmatively says isn't needed. The Supreme Court agreed, overturning a $1.25 million Missouri verdict in the process.Consider why this is such a powerful tool for Bayer. A failure-to-warn claim says, in essence, “you should have told me this was dangerous.” But if the federal agency in charge has studied the product and decided no warning is warranted, then a state jury ordering the company to warn anyway would effectively be overriding the federal regulator. Preemption resolves that conflict in favor of the federal standard. The practical effect is that the single most common theory in the Roundup litigation—failure to warn—is now largely off the table in the cases this ruling reaches.The significance is real but, importantly, not total. This should let Bayer dismiss current warning-based claims and block future ones, which is exactly why the company is now pressing courts to wind down the federal litigation, and it's pairing that push with a proposed $7.25 billion class-action settlement to sweep in remaining Roundup users. But the decision doesn't make every claim disappear. Plaintiffs may still pursue theories that don't depend on a failure to warn—like defective design—and the settlement obligations remain. So this is a milestone in Bayer's long campaign to contain its liability, not the final word. It's also a notable example of how federal regulatory findings can become a shield against state tort law, a doctrine with implications well beyond weedkiller.Bayer seeks end to federal Roundup litigation after Supreme Court win | ReutersFederal judges are sounding skeptical of a California law that bans employers from forcing workers to attend so-called “captive audience” meetings—mandatory gatherings where a company shares its views on political or religious matters, most often its opposition to unionizing. The law has already been blocked by a district court, and the signs from the bench suggest that skepticism may carry through on appeal.Here's what a captive audience meeting is and why it's contested. When a union organizing drive is underway, employers have long held mandatory meetings where attendance is required and workers listen to management make the case against unionizing. Unions call these coercive; employers call them protected speech. California's SB 399 tried to ban compelling attendance at meetings covering “political matters,” a category defined broadly enough to include unionization. Judge Daniel Calabretta of the Eastern District of California blocked the law, and his reasoning is the crux of the whole fight.He gave two independent grounds, and it's worth separating them. The first is federal preemption—the same principle at work in the Bayer story. Calabretta found that the National Labor Relations Act, which governs labor relations nationwide, occupies this field and preempts California's attempt to regulate it under the Machinists and Garmon preemption doctrines. The second ground is the First Amendment: he held that the law was a content-based restriction on employer speech, singling out “political” and “religious” topics, and that it couldn't survive strict scrutiny—the most demanding test in constitutional law, which almost nothing passes. In his view, banning all speech on those topics in mandatory meetings swept far too broadly.The significance here is that this is a collision between the labor movement's priorities and employers' free-speech claims, and right now the free-speech and preemption arguments are winning in court. A number of states have passed captive-audience bans, so how the Ninth Circuit ultimately rules—California and Attorney General Rob Bonta are expected to appeal—will shape whether this entire category of worker-protection law survives. It's a reminder that even popular labor legislation has to run a gauntlet of federal preemption and the First Amendment, and that employer speech, including anti-union speech, gets substantial constitutional protection.US judges leery of California ban on workplace captive-audience meetings | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

In this episode of the Health Upgrade Podcast, Dr. Cindy Howard shares what it's like to experience healthcare from both sides, as a doctor and as a patient. She opens up about her journey of recognizing the signs of Hodgkin's lymphoma in herself and navigating treatment while drawing on her years of experience in functional medicine.Together, we discuss the emotions that come with receiving a life-changing diagnosis, the importance of self-care, and why personalized healthcare can make a real difference. We also explore gut health, environmental toxins, genetic testing, and how AI is changing the way patients can advocate for their own health.Dr. Howard explains why asking questions, setting boundaries, and working with healthcare providers who listen and collaborate are essential parts of achieving better health outcomes.If you or someone you love is lost in the healthcare maze or facing a critical diagnosis, this episode is for you. Listen in, share the episode with a friend, and empower yourself to be an informed, proactive participant in your own health journey!Dr. Navaz HabibEmail: podcast@healthupgraded.comFacebook: https://www.facebook.com/DrNavazHabib/Instagram: https://www.instagram.com/drnavazhabib/LinkedIn: https://ca.linkedin.com/in/drnavazhabibJP ErricoInstagram: https://www.instagram.com/thevnsguy/LinkedIn: https://www.linkedin.com/in/jp-errico-097629aaDr. Cindy HowardWebsite: https://www.innovativehwc.com/

Dorothy Hodgkin's career in X-ray crystallography impacted a lot of science in the 20th century. Part one of her story covers her early life and formative experiences that led her to her field of research. Research: "Dorothy Crowfoot Hodgkin." Encyclopedia of World Biography Online, Gale, 1998. Gale In Context: Opposing Viewpoints, Biophysical Society. “Profiles in Biophysics: Dorothy Hodgkin.” 2016. https://www.biophysics.org/profiles/dorothy-hodgkin Boon, Rachel. “Curator Rachel Boon celebrates the work of Dorothy Hodgkin.” Science Museum. 12/10/2014. https://blog.sciencemuseum.org.uk/celebrating-dorothy-hodgkin-britains-first-female-winner-of-a-nobel-science-prize/ Bragg, Sir William. “Concerning The Nature Of Things.” London. Bell & Sons. 1932. https://archive.org/details/in.ernet.dli.2015.222386/ Bud, Robert. "Discoverers and developers of penicillin (act. 1928–1950)." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-97279 Dodson, Guy. “Dorothy Mary Crowfoot Hodgkin, O.M. 12 May 1910--29 July 1994.” Biographical Memoirs of Fellows of the Royal Society , Dec., 2002, Vol. 48 (Dec., 2002). Via JSTOR. https://www.jstor.org/stable/3650256 DOROTHY CROWFOOT HODGKIN. NobelPrize.org. Nobel Prize Outreach 2026. Wed. 24 Jun 2026. https://www.nobelprize.org/stories/women-who-changed-science/dorothy-hodgkin/ Ferry, Georgina. "Dorothy Hodgkin". Encyclopedia Britannica, 8 May. 2026, https://www.britannica.com/biography/Dorothy-Hodgkin. Accessed 24 June 2026. Ferry, Georgina. "Hodgkin, Dorothy Mary Crowfoot (1910–1994), chemist and crystallographer." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-55028 Ferry, Georgina. “Dorothy Hodgkin: A Life.” Bloomsbury. 1998, 2014. Ferry, Georgina. “Dorothy Hodgkin: on proteins and patterns.” The Lancet, 384, 1496-1497. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61912-7/fulltext Ferry, Georgina. “The making of an exceptional scientist.” Nature. Vol. 464. April 29, 2010. Gamble, Jessa. “When Hodgkin met Thatcher.” Nature. Vol. 514. October 16, 2014. Hodgkin, Dorothy Crowfoot. “The X-ray analysis of complicated molecules.” Nobel Lecture, December 11, 1964. https://www.nobelprize.org/uploads/2018/06/hodgkin-lecture-1.pdf Hodgkin, Dorothy. “The Pugwash Movement.” India International Centre Quarterly. Vol. 13, No. 2. June 1986. Via JSTOR. https://www.jstor.org/stable/23001474 Howard, Judith A.K. “Dorothy Hodgkin and her contributions to biochemistry.” Nature Reviews. Vol. 4. November 2003. gale.com/apps/doc/K1631003072/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=8d7c4045. Accessed 23 June 2026. Pearce, JMS. “Dorothy Crowfoot Hodgkin OM, FRS (1910-1994).” Hektoen International. https://hekint.org/2020/11/04/dorothy-crowfoot-hodgkin-om-frs-1910-1994/ Perutz, Max. “Dorothy Crowfoot ” The Independent. Via The Crystallographic Community. https://www.iucr.org/people/crystallographers/dorothy-crowfoot-hodgkin-by-m.f.-perutz Pietzsch, Jochim. “Perspectives: Enhancing X-ray vision.” Nobel Prize. https://www.nobelprize.org/prizes/chemistry/1964/perspectives/ Ramaseshan, S. “Dorothy Hodgkin and the Indian Connection.” Notes and Records of the Royal Society of London , Jan., 1996. http://www.jstor.com/stable/531845 Root-Bernstein, Robert. “Dorothy Crowfoot Hodgkin: Structure as Art.” Leonardo , 2007, Vol. 40, No. 3 (2007). Via JSTOR. https://www.jstor.org/stable/20206415 Science History Institute Museum and Library. “Dorothy Crowfoot Hodgkin.” https://www.sciencehistory.org/education/scientific-biographies/dorothy-crowfoot-hodgkin/ The Royal Society. “Dorothy Hodgkin FRS.” https://royalsociety.org/about-us/who-we-are/diversity-inclusion/case-studies/scientists-with-disabilities/dorothy-hodgkin/ “Science for peace Building cultures of cooperation and non-violence through scientific collaboration.” 2025. Via JSTOR. https://www.jstor.org/stable/resrep73183.6 University of Oxford History of Science Museum. “Modelling the Structure of Penicillin.” https://www.mhs.ox.ac.uk/backfromthedead/exhibition/the-structure-of-penicillin/index.html Vijayan, M. “An outstanding scientist and great humanist: An obituary of Dorothy Crowfoot Hodgkin.” Current Science, 10 August 1994, Vol. 67, No. 3 (10 August 1994). Via JSTOR. https://www.jstor.org/stable/24095820 Wallace, Rob. “Dorothy Crowfoot Hodgkin: Captured by Crystals.” National World War II 3/16/2022. https://www.nationalww2museum.org/war/articles/dorothy-hodgkin-penicillin-insulin See omnystudio.com/listener for privacy information.

In our latest podcast, Professor Andy Davies, Professor of Haematological Oncology at the University of Southampton and Dr Cathy Burton, Consultant Haematologist at Leeds Teaching Hospital talk to Lymphoma Action's Anne Hook. They talk about how lymphoma management has changed over the past 40 years and discuss how lymphoma treatment and care may look in the future. Forty years ago, the diagnosis of lymphoma was much simpler, with high-grade, low-grade and Hodgkin lymphoma being the main entities. Since the 1980s, techniques have developed to enable more accurate diagnoses and a greater understanding of lymphoma biology. Today, instead of three main types of lymphoma, there are over 100 different subtypes. This means that instead of the blunt approach to treatment 40 years ago where ‘one size fits all', clinicians today are able to deliver more individualised treatment. Andy Davies and Cathy Burton talk about the introduction of the monoclonal antibody rituximab in the 1990s, which has had a major impact. In the podcast they also talk about improvements in cellular therapies, resulting in improvements in transplantation and the introduction of CAR-T cell therapy for some types of lymphoma. Looking to the future, bispecific antibodies and targeted therapies will help improve effectiveness while minimising toxicity and provide the opportunity for different approaches to treatment delivery.Lymphoma Voices is a series of podcasts for people living with lymphoma, and their family and friends. In each podcast, we are in conversation with an expert in their field, or someone who has been personally affected by lymphoma, who shares their thoughts and experiences. Lymphoma Action is the only charity in the UK dedicated to supporting people affected by lymphoma. We are here to make sure that everyone affected by the condition receives the best possible information, support, treatment and care. Our services include a Freephone helpline, support group network, Buddy Service, medical information, conferences for those affected by lymphoma, and education and training for healthcare professionals. We would like to thank all of our incredible supporters whose generous donations enable us to offer all our essential support services free of charge. As an organisation we do not receive any government or NHS funding and so every penny received is truly valued. From everyone at Lymphoma Action and on behalf of those affected by lymphoma, thank you. For further information visit: www.lymphoma-action.org.uk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts reshaping the industry landscape. To begin, the U.S. Food and Drug Administration has taken a noteworthy step by selecting key industry players, including Eli Lilly, Regeneron, Fujifilm, and Kriya Therapeutics, for its PreCheck pilot program. This initiative is designed to enhance U.S. drug manufacturing capabilities, emphasizing the importance of robust domestic production. By reducing dependency on international supply chains, the program aims to expedite the delivery of critical therapies, highlighting a strategic move towards self-reliance in pharmaceutical manufacturing. In oncology news, Beone's Brukinsa (zanubrutinib), a small molecule BTK inhibitor, has demonstrated a remarkable 43% reduction in risk of progression for patients with first-line mantle cell lymphoma in its Phase 3 trial. This breakthrough offers a promising chemotherapy-free option for non-Hodgkin lymphoma treatment, marking significant progress in targeted cancer therapies that could improve patient outcomes in previously underserved areas. Meanwhile, Boulevard Bio and Metis TechBio have sealed a substantial licensing agreement valued at $1.6 billion for MTS-128, a trispecific T-cell engager aimed at autoimmune diseases. This collaboration reflects a broader industry trend towards leveraging advanced AI and machine learning technologies to enhance the development of precision medicine and personalized therapies. Such partnerships indicate a shift towards more innovative approaches to tackling complex disease mechanisms and illustrate burgeoning interest in multispecific biologics within immunotherapy domains—offering new avenues for targeting multiple disease pathways simultaneously. On the regulatory front, Sanofi is advancing efforts to expand the U.S. label for Nexviazyme (avalglucosidase alfa) following successful Phase 3 trials for infantile-onset Pompe disease. As an enzyme replacement therapy targeting GAA enzyme deficiency, Nexviazyme could address a critical gap in treatment options for this debilitating genetic disorder, underlining the importance of regulatory pathways in facilitating access to life-saving therapies. Financially, Beeline Medicines has garnered $126.3 million in Series A extension funding to propel its autoimmune programs originally sourced from Bristol Myers Squibb. Similarly, SmartBax has raised €6.3 million to advance its lead antibiotic program targeting multi-drug resistant infections. These investments underscore an unwavering focus on addressing unmet medical needs through innovative therapeutic solutions. Regulatory challenges persist as well; Unicycive Therapeutics faced FDA rejection due to third-party manufacturing deficiencies surrounding oxylanthanum carbonate. This setback emphasizes the critical importance of maintaining rigorous quality standards throughout drug production processes to secure regulatory approvals and ensure patient safety. Globally, China has achieved a milestone with the approval of the world's first CAR-T therapy for solid tumors—a significant leap forward given the historical challenges of applying CAR-T technology beyond hematological malignancies. This approval could transform cancer treatment paradigms globally and prompt similar regulatory advancements in other regions. In other developments, Abbvie and Genmab's combination therapy involving Epkinly has shown promise in diffuse large B-cell lymphoma (DLBCL) trials following prior challenges with monotherapy approaches. This success story highlights the potential of combination therapies in enhancing outcomes for patients battling complex cancers like DLBCL. From a corporate perspective, Klick Health's acquisition of Oxford Pharmagenesis marks its third purchase in 18 months, expanding its global footprint and scientific capabilities—a testament to ongoing consolidation trends aimed at augmenting expertise and strategic growth within the sector. These developments collectively paint a picture of an industry dynamically evolving amidst scientific breakthroughs and regulatory recalibrations. As companies navigate this transformative landscape, their ability to adapt and innovate remains paramount for sustaining growth and addressing global healthcare challenges effectively. Stakeholders must remain agile to seize opportunities while mitigating inherent risks in this high-stakes environment that increasingly prioritizes patient-centric innovations.Support the show

This week we welcome the boy Foster Moreau back to the pod, and it's safe to say Foster has had one of the craziest offseasons of all NFL Players. The boys immediately get some hot takes about some actor as well as get into some conspiracy theories. Foster shares some stories of his time at LSU about different bars he used to go to and just the town itself. The boys then get into Foster’s crazy offseason. He was diagnosed with Hodgkin's Lymphoma in March while on a visit to the Saints. He shares the story of how he found out from his physical and the exact type of cancer he was diagnosed with. Foster gets into what it was like telling his family and friends and how difficult it was. The boys then lighten the mood as they get into how he has officially been signed to the New Orleans Saints and is reunited with Derek Carr. The boys end the pod with a legendary Tier Talk of best iPhone games. Foster was super open with the boys and it is no doubt a must listen. Enjoy.See omnystudio.com/listener for privacy information.

Jonathon Cohen, MD, MS When you hear the word “aggressive,” it can feel overwhelming, but in diffuse large B-cell lymphoma (DLBCL), it can also point to something encouraging – a potential cure. In this episode, we speak with Dr. Jonathon Cohen, of Winship Cancer Institute in Atlanta, GA, about what a DLBCL diagnosis really means, from how this common type of non-Hodgkin lymphoma is identified to current treatment options and emerging therapies. We explain what patients and families need to know about side effects. We also look at new treatments, including CAR T-cell therapy and bispecific antibodies, and the importance of open communication with your care team. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Diffuse large B-cell lymphoma CAR T-cell therapy Stem cell transplantation Bispecific antibodies (immunotherapy fact sheet) Clinical Trial Support Center Additional Blood Cancer United Support Resources: Information Specialists Young Adult Resources Young Adult Online Chat Financial support Free Nutrition Consultations Free telephone/web patient programs SHARE web series Online videos Free booklets Patient Community Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by Genmab US, Inc.The post Diffuse Large B-Cell Lymphoma (DLBCL): Breaking Down an Aggressive Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.

What would you do if you moved out to LA at 18 to chase your dreams, but got handed a non-Hodgkin's lymphoma diagnosis and a 5-year expiration date instead? Our guest Aria fought through chemo, radiation, and 16 separate surgeries, and actually beat it. But the universe wasn't done with her. After just two months of remission, the cancer moved to the temporal lobe of her brain, and doctors gave her one year to live. Spoiler alert: she didn't die. Aria decided to surrender to whatever was going to happen and somehow beat terminal brain cancer. But just when she thought she was in the clear, celebrating her one-year cancer-free anniversary on a road trip to Wyoming, she passed out at the wheel and crashed her car at 80 mph. The impact shattered her occipital bone, essentially detaching her skull from her spine. She woke up completely blind, unable to speak, and unable to walk. Buckle up (literally and figuratively) for a real life Final Destination style episode. Aria is a radiant, unkillable badass, and this conversation is a masterclass in fearless resilience. Follow Sickboy: Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDN

What would you do if you moved out to LA at 18 to chase your dreams, but got handed a non-Hodgkin's lymphoma diagnosis and a 5-year expiration date instead? Our guest Aria fought through chemo, radiation, and 16 separate surgeries, and actually beat it. But the universe wasn't done with her. After just two months of remission, the cancer moved to the temporal lobe of her brain, and doctors gave her one year to live. Spoiler alert: she didn't die. Aria decided to surrender to whatever was going to happen and somehow beat terminal brain cancer. But just when she thought she was in the clear, celebrating her one-year cancer-free anniversary on a road trip to Wyoming, she passed out at the wheel and crashed her car at 80 mph. The impact shattered her occipital bone, essentially detaching her skull from her spine. She woke up completely blind, unable to speak, and unable to walk. Buckle up (literally and figuratively) for a real life Final Destination style episode. Aria is a radiant, unkillable badass, and this conversation is a masterclass in fearless resilience. Follow Sickboy: Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDN

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals about the launch of its first FDA-approved drug, Lymphir, for CTCL. Mazur discusses the landscape of unmet need in this space, as well as Citius' advancement of clinical trials in other areas without approved treatments and the future horizon for such oncological innovations. You can listen to episode 265 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Why does bread in Europe not bother your gut the way it does in the United States — and what does glyphosate have to do with Hashimoto's, hypothyroidism, and other serious health conditions? If wheat and dairy trigger inflammation, fatigue, anxiety, or loose stools at home, why can they feel totally fine abroad? In this episode, I share what happened when I recently spent two weeks in Spain and Portugal and ate gluten after being gluten-free for 14 years. Instead of feeling bloated, irritable, and anxious like I normally would after eating gluten, I actually felt completely fine. That's right — no symptoms whatsoever. You've probably heard of others having similar experiences, but the science and history behind why this happens is fascinating. I explain why European wheat is different from U.S. wheat, and how the U.S. food system's agricultural and dairy practices have created a perfect storm of problems since at least 1996. We'll get into how glyphosate and other herbicides have infiltrated our food system, plus what the research says about gut bacteria disruption, intestinal permeability, and thyroid/endocrine impacts. There's also a very real connection between glyphosate and non-Hodgkin lymphoma that has led to hundreds of thousands of lawsuits. Then we talk dairy: why the EU banned synthetic growth hormones, fatty acid profiles (grass-fed vs. grain-fed), and how mold-contaminated feed can contribute to issues that I often see show up in toxin testing. This may all seem like bad news from the U.S. perspective, but there are still things we can do here to protect our health without missing out on the good things in life. One major benefit of living in the U.S. is that there are unlimited options, and there are many swaps we can make that avoid the toxins and inflammatory ingredients. And maybe, this is even the sign you need to take that much-deserved vacation to test out Europe's food system for yourself! Disclaimer: This information is being provided to you for educational and informational purposes only. It is being provided to educate you about how to take care of your body and as a self-help tool for your own use so that you can reach your own health goals. It is not intended to treat or cure any specific illness and is not to replace the guidance provided by your own medical practitioner. If you are under the care of a healthcare professional or currently use prescription medications, you should discuss any dietary changes or potential dietary supplement use with your doctor, and should not discontinue any prescription medications without first consulting your doctor. This information is to be used at your own risk based on your own judgment. If you suspect you have a medical problem, we urge you to take appropriate action by seeking medical attention.In This Episode: [2:30] The 2 most common food triggers in my clients[6:20] Why grains and wheat hit differently in Europe than they do in the US[7:45] What is GMO and glyphosate?[11:25] How glyphosate affects the body — the link to non-Hodgkin lymphoma[19:25] The night I decided to be a functional health practitioner[21:30] The regulatory environment that keeps food in the EU safer[22:43] Dairy in the EU vs. the US[26:25] The missing cultural piece in the US[29:35] How to support our health despite all the bad newsConnect with Sophie: Instagram: @shetalkshealthWebsite: shetalkshealth.comApply to work with us: www.shetalkshealth.com/callThyroid Breakthrough Call: https://thyroidhealthaudit.shetalkshealth.com/thyroid-health-auditThe Mineral Reset (HTMA): https://shethrives.shetalkshealth.com/htma-packageMineral Mocktail (get your energy back now!: https://shetalkshealth.com/mineral-mocktail-guide/Stop guessing with your thyroid & Get Answers Now: https://ace.shetalkshealth.com/home-front

Date: 6/18/26Name of podcast: Dr. PatientEpisode title and number: 33 Second Opinions in HealthcareEpisode summary: In Episode 33 of Dr.Patient, host and physician Dr. Heather Johnston is joined by two guests — Mia and Joby — to share their personal experiences navigating the medical second opinion process after serious cancer diagnoses. Mia, a breast cancer survivor, and Joby, who faced three separate cancer diagnoses including bone cancer and Hodgkin's lymphoma, open up about the emotional, logistical, and financial hurdles of seeking second opinions — from tracking down pathology slides and paying out-of-pocket fees to encountering dismissive surgeons and conflicting treatment recommendations. Together, they explore why patients seek second opinions (complex diagnosis, distrust, rare illness), what happens when doctors disagree on cancer treatment, and how factors like bedside manner, doctor-patient trust, institutional coordination, and staying current on medical research all influence which physician a patient ultimately chooses. If you've ever wondered whether to get a second medical opinion, how to navigate the healthcare system during a health crisis, or what questions to ask your oncologist, this episode offers honest, real-world insight from both a doctor's and patient's perspective.Guest(s): Joby, MiaPodcast website: www.drpatientpodcast.comPodcast email, become a guest: drpatientpodcast@gmail.com

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Redshirt freshman goalkeeper Rylie Kuyper opens up about her recent cancer diagnosis of Hodgkin's lymphoma with LSU soccer SID Alyssa Leal. Kuyper is remaining in great spirits despite the life-changing news and shares more about her positive outlook for the future. Her story has been picked up from PEOPLE.com, the TODAY Show and other national publications.

What do you learn when you face cancer, not once but twice?Savio P. Clemente has done it and came out the other side to share the squiggly lessons we all need. This episode of Embrace the Squiggle, Colleen and Ashleigh speak with keynote and TEDx speaker, board-certified wellness coach, journalist, and two-time cancer survivor Savio P. Clemente about pressure and post-crisis leadership.Savio recounts being diagnosed in 2014 with stage three non-Hodgkin's lymphoma, undergoing six rounds of R-CHOP, and being cancer-free for a decade before a relapse. His experience fighting cancer tought him the importance of integrative healing, compassion, and the power of silence and stillness.

It's been a tough road for one of our own, but the whole community has been right behind him. Now, the Big Marn has some positive news about his battle with non-Hodgkin's lymphoma.See omnystudio.com/listener for privacy information.

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/05-06-2026Nesta sexta-feira, analisamos atualizações em endocrinologia reprodutiva, uma revolução na terapia celular oncológica e o papel dos jogos sérios no julgamento clínico. Abordamos as diretrizes atualizadas da American Thyroid Association, que estabelecem valores de referência por trimestre para TSH e T4, priorizando o rastreamento direcionado. Detalhamos os dados promissores da nova terapia CAR-T in vivo da Legend Biotech para linfoma não-Hodgkin, que gera as células de defesa diretamente dentro do corpo do paciente. Por fim, discutimos no Radar um estudo do JAMA que comprova como o jogo eletrônico Night Shift reduziu erros médicos e a subestimativa de traumas em idosos na emergência. Afya News. Informação médica confiável e atualizada no seu tempo.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly. Starting with Legend Biotech's LB2501, which achieved an impressive 100% response rate in a Phase 1 study for non-Hodgkin lymphoma using in vivo CAR T-cell therapy. This breakthrough highlights the transformative potential of CAR T-cell therapies in oncology, especially for B-cell lymphomas. Such success opens the door for accelerated regulatory pathways, offering hope to patients with limited treatment options. In another key development, JJP Biologics shared positive interim data from its Phase 1b trial of nebaprubart targeting CD89 in linear IgA disease. This monoclonal antibody is promising in treating autoimmune conditions by targeting specific disease mechanisms. Meanwhile, GSK's Velzatinib (IDRX-42) achieved a 61% response rate in Phase 1/1b trials for gastrointestinal stromal tumors, showing efficacy against cases resistant to treatments like imatinib. Johnson & Johnson's Nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, underscoring the potential of FcRn blockade in managing autoimmune diseases. Zenas Biopharma's Phase 3 data for Obexelimab targeting CD19/FcγRIIB in IgG4-related disease further emphasizes the role of targeted therapies in managing complex autoimmune disorders. On the regulatory front, Foundation Medicine's FoundationOne Blood Test received FDA approval as a companion diagnostic for Pfizer's Talzenna (talazoparib) to treat prostate cancer with homologous recombination repair gene mutations. This approval underscores the growing importance of precision medicine and companion diagnostics in tailoring cancer treatments based on genetic profiles. Additionally, Lupin and Natco Pharma secured FDA approval for their generic version of Eribulin Mesylate Injection, essential for reducing healthcare costs and improving patient access to vital therapies. Eli Lilly's collaboration with Ascidian Therapeutics focuses on RNA exon editing for kidney diseases, potentially revolutionizing treatment approaches by correcting genetic errors at the RNA level. This partnership reflects a burgeoning interest in RNA-based therapies and their capacity to address unmet medical needs. Regeneron expanded its pact with CytomX Therapeutics to develop conditionally active bispecific antibodies, emphasizing innovation in oncology drug discovery. Such collaborations combine expertise across companies to expedite cutting-edge therapies' development. In terms of funding, NewLimit's successful $435 million Series C round aims to advance epigenetic reprogramming medicine towards human trials. This initiative highlights the burgeoning field of aging biology and its implications for extending healthy human lifespan through innovative therapeutic approaches. Similarly, Immu Biosciences raised $53 million to enhance its immunology platform using AI/ML technologies, underscoring AI and machine learning's critical role in accelerating drug development processes. Turning our gaze towards China's expanding influence on the global biotech stage, Akeso's presentation at ASCO 2026 marked a significant milestone as it became the first-ever Chinese dataset featured in a plenary session. This achievement underscores China's growing prominence in biotechnology and highlights its commitment to advancing innovative medical solutions globally. Simultaneously, Gilead's strategic partnership with Cencora aims to enhance access to CAR-T therapies like Yescarta and Tecartus by expanding their network of treatment centers. CAR-T therapies represent a paradigm shift in cancer treatment by offering personalized options for certain types of cancer. Despite challenges such as Roche's setbacks with its oral SERD drug giredestrant in breast cancer trials, innovation continues unabated. Zevra Therapeutics' launch of Miplyffa for Niemann-Pick disease type C exemplifies efforts to transform rare disease markets by improving patient outcomes through increased access and tailored treatment strategies. Finally, Eli Lilly's acquisition spree reflects broader trends where pharmaceutical companies increasingly integrate Chinese innovations into their development pipelines. This period marks a transformative phase characterized by collaboration between global pharma giants and Chinese biotechs, signaling an era where innovation is globalized and aimed at addressing critical healthcare challenges worldwide. These advancements reflect a dynamic period of innovation within the pharmaceutical and biotech industries. The focus on personalized medicine, targeted therapies, and groundbreaking technologies like RNA editing indicates a shift towards more precise treatment modalities. As these discoveries transition from research phases to clinical applications, they hold the potential to transform patient care significantly. Strategic partnerships and substantial funding initiatives illustrate a robust ecosystem supporting these innovations' rapid advancement. As regulatory bodies continue approving novel therapeutics and diagnostics, the emphasis on personalized healthcare will likely drive future developments, ultimately leading to improved patient outcomes worldwide. As we continue navigating these developments, it's clear that the pharmaceutical and biotech sectors are on the cusp of transformative breakthroughs that promise to redefine healthcare delivery across multiple domains. Thank you for tuning into Pharma Daily; stay informed and stay ahead.Support the show

In this inspiring Episode #213 of the Self-Care Goddess Podcast's UpliftHER Leadership Series, I am joined by Maria Locker, Founder & CEO of Revolution Her, entrepreneur, community leader, cancer survivor, and a passionate champion for women rising together through connection, resilience, and empowerment.Maria shares her deeply personal journey of building a movement that has empowered thousands of women while navigating motherhood, entrepreneurship, health challenges, and life's unexpected detours. This conversation is an inspiring reminder that success isn't about perfection, it's about authenticity, resilience, community, and staying true to who you are.Together we explore what it really means to lead with heart in a world that often rewards hustle over humanity.In this episode, you'll discover:✅ Why work-life balance may be the wrong goal and what to focus on instead✅ How Maria built Revolution Her into a thriving community supporting women entrepreneurs✅ The life-changing lessons she learned after being diagnosed with Hodgkin's lymphoma and thyroid cancer✅ Why asking for help is one of the strongest things you can do✅ The hidden signs of burnout most women overlook✅ How perfectionism keeps women stuck and exhausted✅ The importance of community, family, and having a strong support system✅ Why nature, movement, and slowing down can be powerful forms of healing✅ The role of authenticity, vulnerability, and emotional intelligence in leadership✅ How women can embrace softness without sacrificing strength✅ Why comparison is one of the biggest challenges facing younger generations✅ Practical wisdom on resilience, self-care, and navigating uncertain times✅ How to create more flow, joy, and meaning in everyday lifeThis episode is for every woman who has ever felt the pressure to do it all, be everything to everyone, or carry the weight of the world on her shoulders.Maria's story is a beautiful reminder that life doesn't have to be perfect to be wonderful, and that true success is found in meaningful relationships, purposeful work, kindness, curiosity, and the courage to be yourself.If this conversation resonated with you, please like, subscribe, and share it with someone who needs this message today.#SelfCareGoddess #WomenInLeadership #BurnoutRecovery #PersonalGrowth #Mindset #WomenSupportingWomen #Leadership===▸ Toronto Events – Do you live in the GTA? Join us for a transformative in-person Self-Care Breathwork Experience in Toronto with LIVE Music & Sound Bath. ⁠RSVP⁠ ▸ ⁠Ebook – YOU GOT THIS⁠ – A powerful read to stop overthinking, self-sabotaging & staying stuck.▸ ⁠Healthy Breathing Course⁠ – Learn functional breathing to address stress, anxiety & burnout.▸ ⁠Virtual Full Moon Breathwork⁠ – Harness the power of the moon every month online.▸ ⁠Breathwork Barista Espresso Shots – Join our 30-mins functional breathing sessions. ▸ ⁠Breathwork Barista Inner Circle⁠ – Join a soul-aligned community for conscious growth.▸ Free Resources:– ⁠Mental Health Shopping List⁠ – ⁠9 Vital Breathing Techniques⁠ – ⁠Workplace Wellness Calendar⁠  Follow & Connect:Instagram | ⁠Rita Savoia⁠ | ⁠Breathwork Barista⁠ ⁠Facebook⁠ X⁠ TikTokYouTubeDisclaimer: Content on this podcast is for educational purposes only and not a substitute for professional medical advice. Always consult your healthcare provider for personal health concerns.

Dakota Carson was diagnosed with Hodgkin's lymphoma inJanuary, and his response was to prepare for war. In this episode of Alex Perry on Fire, Dakota walks through the long road to his diagnosis, the new immunotherapy and chemotherapy plan that cut his treatment nearly in half, andthe mindset carrying him through it. A candid conversation about facing cancer head on, leaning on family, and finding strength when no one else can see the fight.Your turn to start the fire.Like what you heard today on Alex Perry on Fire? Tell usabout it. Want to share what has helped you on your journey? We want to hear about that, too.Comment on social, DM us or give us a call. Instagram: @alexperryonfire    TikTok: @alexperryonfireCall: 214-506-8023

Swanny opens the show by reflecting on Memorial Day before diving into the ACC Baseball Championship, where Georgia Tech Yellow Jackets baseball capped off a dominant season with a convincing win over North Carolina Tar Heels baseball. He also discusses Clemson football's recent recruiting surge as the Tigers add five commitments in a week, including Carter Blackwell and Carter Jones, while examining the realities of recruiting in the NIL era and why commitments today must be viewed differently than ever before.The show then shifts to more meaningful news as Clemson defensive tackle Hevin Brown-Shuler speaks publicly for the first time about his battle with Hodgkin lymphoma. Swanny shares comments from both Brown-Shuler and Dabo Swinney, highlighting the support surrounding the young Tiger and the positive outlook for his recovery. Later, Swanny pays tribute to former Clemson athletic director Terry Don Phillips following news of his passing. From hiring Dabo Swinney to shaping the future of Clemson athletics through landmark coaching hires and facility improvements, Swanny reflects on Phillips' lasting legacy and the impact his belief and leadership continue to have on Clemson today. The show wraps up with a look at the NCAA Baseball Tournament field, the NBA and NHL playoffs, and what lies ahead for college baseball's postseason.

Can loosening one's grip on long-held beliefs lead to renewed vitality and extended time to cherish life? Dancer, wordsmith and data squirrel Yvonne Shapiro shares how shifting from resistance to acceptance influenced her journey with breast cancer and non-Hodgkin's lymphoma. She explores the raw terrain of fear, trauma and joy, and “being both well and ill at the same time.” This episode's podcast notes and photographs · www.mariettesnyman.co.za · www.facebook.com · www.instagram.com · www.linkedin.com

Swanny opens the show breaking down the wild start to the ACC Baseball Tournament after Duke Blue Devils baseball outslugged NC State Wolfpack baseball 21-12 in a four-hour marathon that pushed back Clemson's matchup with Notre Dame Fighting Irish baseball in Charlotte.Plus, Swanny reacts to the difficult news surrounding Clemson defensive tackle Hevin Brown-Shuler's Hodgkin lymphoma diagnosis and shares thoughts on the support pouring in from the Clemson community. 

Dr Bill Nelson talks with YouTuber and science communicator Hank Green about his diagnosis and treatment for Hodgkin lymphoma, the quickening of advances in cancer therapies and the most likely areas for future care breakthroughs.

A lot happened at the NFL owner's meeting and Ryan's got all of it. Nashville officially gets Super Bowl 64 in 2030. Minnesota gets the 2028 draft — good news for Packer fans within driving distance. International games are expanding to 10 per season starting in 2027, with Goodell eyeing 16 eventually. Ryan's cautiously okay with the expansion until someone says Japan, at which point he's fully on board and also realizes he'll never actually go. The Bears got a special briefing on their stadium situation, because the other 31 owners apparently need a progress report on why Chicago still doesn't know where their team plays. The only two viable options remain Arlington Heights and Hammond, Indiana — meaning the days of Bears fans talking trash about small-town Wisconsin are officially over. Ryan has thoughts. Also: Rashee Rice is in jail after a marijuana violation voided his deferred sentencing. Josh Sweat is unhappy in Arizona, Ganon is in Green Bay, and Ryan does the math on what a third-round pick for a number-three edge rusher might look like. He's making that call. And finally — the Packers briefly discussed bringing Davante Adams back before it went nowhere, and they signed Vanderbilt DB Marlon Jones, who beat stage-three Hodgkin's lymphoma last year and is the feel-good story of the offseason.

A lot happened at the NFL owner's meeting and Ryan's got all of it. Nashville officially gets Super Bowl 64 in 2030. Minnesota gets the 2028 draft — good news for Packer fans within driving distance. International games are expanding to 10 per season starting in 2027, with Goodell eyeing 16 eventually. Ryan's cautiously okay with the expansion until someone says Japan, at which point he's fully on board and also realizes he'll never actually go. The Bears got a special briefing on their stadium situation, because the other 31 owners apparently need a progress report on why Chicago still doesn't know where their team plays. The only two viable options remain Arlington Heights and Hammond, Indiana — meaning the days of Bears fans talking trash about small-town Wisconsin are officially over. Ryan has thoughts. Also: Rashee Rice is in jail after a marijuana violation voided his deferred sentencing. Josh Sweat is unhappy in Arizona, Ganon is in Green Bay, and Ryan does the math on what a third-round pick for a number-three edge rusher might look like. He's making that call. And finally — the Packers briefly discussed bringing Davante Adams back before it went nowhere, and they signed Vanderbilt DB Marlon Jones, who beat stage-three Hodgkin's lymphoma last year and is the feel-good story of the offseason.

Today's guest is Carmen Monge, Hodgkin's Lymphoma survivor, researcher, and patient advocate working at the intersection of lived experience, research, and equity in cancer care, especially across different global healthcare systems.Carmen is the founder of MANO Beyond Cancer, a global initiative exploring survivorship through qualitative research, where she had conducted interviews with survivors from more than 60 countries. She also works as a researcher and patient advocate with Youth Cancer Europe. And the author of CAN-CAN, a children's book series designed to help explain the cancer journey, from diagnosis to life after treatment, in a holistic and accessible way.We talk about hope, cancer research, cultural differences and disparities in cancer care, the challenges of getting treatment is another country from your homeland, common threads among survivors globally, and so much more!!!Resources:Carmen's YouTube channel: https://www.youtube.com/@MANObeyondcancerCarmen's Instagram: https://www.instagram.com/mano_beyondcancer/Carmen's contact info: https://linktr.ee/CarmenMongeFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Ep. 205 - Join Kimberly for part 2 of her deep-dive with the incredibly talented and incredibly inspiring Charles Porter. Last week, we got to know Charles as a Duke football player turned Hollywood entrepreneur. Today, we go deeper into the mindset that makes Charles a survivor, a leader, and a beacon of hope. We discuss his career as an actor, a producer, and his battles with stage 4 Hodgkin's lymphoma. Discover how Charles uses the power of brainwashing, creates strict boundaries, and goes all-in on life to navigate his cancer journey.  Chapter Timestamps: 1:15 - Duke Football & The NFL: Transitioning from football to a new career path. 6:42 - Hollywood Bound: Charles' early years in LA, including his first job in marketing and landing a role on ESPN's "Beg, Borrow, or Deal". 10:11 - Producing & The Hollywood Grind: Shifting gears to producing and finding proactive ways to grow in his career. 13:17 - Stage 4 Cancer Diagnosis: Charles shares the poignant story of his cancer diagnosis, the physical symptoms he missed, and the emotional impact on his life and relationships. 21:55 - The Cancer Journey & Treatment: Charles discusses his experience with three bone marrow transplants, various treatments, and the emotional battle he and his family faced. 27:14 - The Power of the Mindset: Discover Charles' concept of "brainwashing for greatness" and how he used positive affirmations and visualization to stay strong during his treatments. 31:47 - Creating Strong Boundaries: The importance of choosing your circle wisely and ruthlessly protecting your peace. 38:39 - Dealing with Negative Perceptions: Charles' perspective on dealing with mischaracterization and character assassination. 41:40 - The Path to Wisdom & Peace: A discussion on ego, accountability, and his quest for a life of meaning and authenticity. Follow Charles on Instagram: https://www.instagram.com/cfpgram/ And Black Bench Productions: https://www.instagram.com/blackbenchproductions/ Follow Kimberly on Instagram: https://www.instagram.com/kimberlylovi/ Subscribe on YouTube Here: ‪https://www.youtube.com/@iconicnationmedia      

Host and American Family Farmer, Doug Stephan (www.eastleighfarm.com) shares the biggest news affecting smaller family farmers, starting with the Farm Bill. The House is working on another draft Farm Bill, continuing with the hold up. Additionally, the U.S. House passed the Farm, Food, and National Security Act of 2026 (H.R. 8467) on April 30, 2026, with a 224-200 bipartisan vote, advancing a new five-year farm bill that strengthens crop insurance, raises commodity reference prices, and reauthorizes USDA programs through 2031. The bill now faces a difficult path in the Senate, where it needs 60 votes to overcome a filibuster. The Farm Bill also contains significant changes to SNAP (food assistance), which has been a major point of debate, with many questioning why this is even included on this bill at all. Moving along, a new study suggests people living in areas with heavy pesticide use face significantly higher risk of cancer. The research suggests that combinations of pesticides, even those considered safe individually, can act together to damage cells, suggesting environmental exposure is a major, previously underestimated factor in cancer rates. Regions with high agricultural activity, specifically the US Midwest, showed significantly higher cancer incidence, with some estimates suggesting risks comparable to or higher than smoking for certain cancers. The study found that "pesticide cocktails"—combinations of chemicals (like Glyphosate, Atrazine, and [Dicamba])—multiply cancer risk, rather than any single chemical acting alone. Even pesticides deemed "non-carcinogenic" individually by regulatory standards appear to contribute to cancer risk when combined in the environment. Researchers identified that these mixtures can disrupt liver cells—a primary detoxification organ—years before a cancer diagnosis. The study linked higher exposure to increased rates of leukemia, non-Hodgkin's lymphoma, and cancers of the bladder, colon, lung, and pancreas. In case you missed it, May is Mental Health Month. The American Farm Bureau Federation (AFBF) Farm State of Mind campaign, supported by the Farm State of Mind Alliance formed in 2025, works to reduce mental health stigma and increase access to resources for farmers and ranchers. The initiative provides a national directory, free counseling, and training to support mental wellness in rural communities. Founded by AFBF, National Farmers Union, National 4-H Council, and Farm Foundation, the Alliance brings together trusted voices to make, “It's okay not to be okay,” a standard in agricultural communities. The campaign utilizes initiatives like farm-focused mental health articles in magazines and on TV. The campaign emphasizes May as Mental Health Awareness Month to reach out to neighbors in the agricultural community.For more on the American Family Farmer…Website: AmericanFamilyFarmerShow.comSocial Media: @GoodDayNetworks

Shell Rowe was diagnosed with Stage 4 non-Hodgkin lymphoma at just 20 years old. Somehow, she found the humour in cancer, building a social following of over 1.1 million. In this episode, she joins Dr Alex George to share the devastating conversations that followed her diagnosis - including telling her girlfriend she didn't need to stay - and the moment which left her thinking ‘it's now or never'. Plus, she shares why she believes cancer is as much of a mental battle as a physical one, and why it's the little moments you'd realise you'd miss. Follow @shellrowex and pre order her book Dying to Live: How to Thrive, Not Just Survive(By using our affiliate bookshop you'll help fund Stompcast by earning a small commission for every sale. Bookshop.org's fees help support independent bookshops too!)Order Alex's latest book Am I Normal? - out now!Order Happy Habits - out now! Follow the podcast on Instagram @thestompcastGet the new, pocket guide version of The Mind Manual nowDownload Mettle: the mental fitness app for men Hosted on Acast. See acast.com/privacy for more information.

Please visit answersincme.com/860/102771731-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sairah Ahmed, MD; and Sharon Marie Castellino, MD, MSc. In this activity, experts in Hodgkin lymphoma discuss unmet needs and emerging data in the treatment of classical HL. Upon completion of this activity, participants should be better able to: Explain the rationale for investigating ICI-based regimens for previously untreated advanced cHL; Interpret the emerging clinical evidence for ICI-based regimens in patients with previously untreated advanced cHL; and Propose how emerging ICI-based regimens, as they become available, may fit into the treatment paradigm for adult and pediatric patients with previously untreated advanced cHL.

One heavy squat at 400 pounds was all Kalil Sherrod needed to know the poison hadn't won. Seven weeks before this recording, Kalil walked into elitefts HQ to hit his first major milestone since a brutal cancer diagnosis. That moment bridged the gap between his life as an elite performance coach and his reality as a survivor. Through two stem cell transplants and multiple rounds of high-intensity chemotherapy, he developed a conjugate-based survival blueprint—one that reinforces a hard truth: muscle mass is one of the most powerful insurance policies for the human body. Inside the Episode: The 93% Rule: Why maintaining a high performance floor matters more than chasing a peak during a competitive season Conjugate for the Court: Applying Westside methodology to basketball players without sacrificing vertical jump or shooting touch Training Through the Storm: How Kalil adjusted his training split during "ICE" chemotherapy to preserve lean tissue The Youth Development Gap: Why the loss of PE and martial arts is producing more fragile athletes—and how to reverse it The IV Protocol: A critical hydration strategy often overlooked during medical treatment Meet the Guest: Kalil Sherrod is a high-performance coach, author, and founder of Revenants Coaching. A former Division II basketball player, he serves as a Sports Performance Coach for the Thailand Titans and works with athletes at The Spot Athletics. He is the author of The Basketball Player's Training Guide and co-author of the elitefts eBook Mastering Conjugate Programming for Athletes. After surviving Hodgkin's Lymphoma, Kalil has dedicated his work to helping athletes and survivors use strength as a foundation for resilience. Connect with Kalil Sherrod: Instagram: https://www.instagram.com/kalil_sherrod YouTube: https://www.youtube.com/@kalilsherrod4882 Linktree: https://linktr.ee/kalilsherrod The Get Clean Podcast: https://podcasters.spotify.com/pod/show/kalil-sherrod7 The Spot Athletics: https://www.thespotathletics.com Revenants Coaching: https://linktr.ee/kalilsherro Become an elitefts Channel Member: Get early access to Dave Tate's Table Talk and more: @eliteftsofficial Support Dave Tate's Table Talk: FULL Crew Access: https://www.elitefts.com/join-the-crew Limited Edition Apparel: https://www.elitefts.com/shop/apparel/limited-edition.html Programs & More: https://www.elitefts.com/shop/dave-tate-s-table-talk-crew.html TYAO Application: https://www.elitefts.com/dave-tate-s-tyao-application Best-Selling elitefts Products: Pro Resistance Bands: https://www.elitefts.com/shop/bands.html Specialty Barbells: https://www.elitefts.com/shop/bars-weights/specialty-bars.html Wraps, Straps, Sleeves: https://www.elitefts.com/shop/power-gear.html Sponsors: Get an extra 10% OFF at elitefts (CODE: TABLE TALK): https://www.elitefts.com/ Get 10% OFF Marek Health Labs (CODE: TABLETALK): https://marekhealth.com/tabletalk Free 8-count LMNT Sample Pack: http://www.drinklmnt.com/tabletalk Support Massenomics: https://www.massenomics.com/ Save 20% on MASS Research Review (CODE: ELITEFTS20): https://massresearchreview.com/ Get 10% OFF RP Hypertrophy App (CODE: TABLE TALK): https://rpstrength.com/pages/hypertrophy-app

One heavy squat at 400 lbs was the only signal Kalil Sherrod needed to know the poison hadn't won yet. Seven weeks before recording this episode, Kalil walked into elitefts HQ to hit his first heavy milestone since a grueling cancer diagnosis—a moment that bridged the gap between his life as an elite performance coach and his reality as a survivor. Through two stem cell transplants and rounds of high-intensity chemo, he has refined a conjugate-based survival blueprint that proves muscle mass is the ultimate insurance policy for the human immune system. INSIDE THE EPISODE: The 93% Rule: Why maintaining a high performance floor is more critical than chasing a ceiling during a competitive season. Conjugate for the Court: How to apply Westside methodology to basketball players without sacrificing their vertical or shooting touch. Training Through the Storm: The specific adjustments Kalil made to his training split while undergoing "ICE" chemotherapy to preserve lean tissue. The Youth Developmental Gap: Why the loss of traditional PE and martial arts is creating a generation of fragile athletes and how to fix it. The IV Protocol: A critical, overlooked hydration tip for anyone navigating medical treatments that often gets ignored by hospital staff. MEET THE GUEST: Kalil Sherrod is a high-performance coach, author, and the founder of Revenants Coaching. A former DII basketball player, he currently serves as the Sports Performance Coach for the Thailand Titans professional basketball organization and coaches at The Spot Athletics. Kalil is the author of The Basketball Player's Training Guide and co-author of the elitefts eBook Mastering Conjugate Programming for Athletes. After surviving Hodgkin's Lymphoma, he has dedicated his work to helping athletes and fellow survivors use strength as a tool for radical resilience. CONNECT WITH KALIL SHERROD: Instagram: https://www.instagram.com/kalil_sherrod YouTube: https://www.youtube.com/@kalilsherrod4882 Linktree: https://linktr.ee/kalilsherrod The Get Clean Podcast: https://spotify.com/0 The Spot Athletics: https://www.thespotathletics.com Revenants Coaching: https://linktr.ee/kalilsherro SUPPORT DAVE TATE'S TABLE TALK: FULL Crew Access: https://www.elitefts.com/join-the-crew Limited Edition Apparel: https://www.elitefts.com/shop/apparel/limited-edition.html Programs & More: https://www.elitefts.com/shop/dave-tate-s-table-talk-crew.html TYAO Application: https://www.elitefts.com/dave-tate-s-tyao-application ELITEFTS GEAR: Pro Resistance Training Bands: https://www.elitefts.com/shop/bands.html Specialty Barbells: https://www.elitefts.com/shop/bars-weights/specialty-bars.html Wraps, Straps, Sleeves: https://www.elitefts.com/shop/power-gear.html SPONSORS: elitefts: (CODE: TABLE TALK) https://www.elitefts.com/ Marek Health Labs: (CODE: TABLETALK) https://marekhealth.com/tabletalk LMNT: (Free Sample Pack) http://www.drinklmnt.com/tabletalk Massenomics: https://www.massenomics.com/ MASS Research Review: (CODE: ELITEFTS20) https://massresearchreview.com/ RP Hypertrophy App: (CODE: TABLE TALK) https://rpstrength.com/pages/hypertrophy-app

This is not a medical episode — it's an episode born from care. When Sheila's daughter was diagnosed with Hodgkin's lymphoma, sewing became one of the ways she could offer comfort and dignity during treatment. In this episode, Sheila of SheilaLovesFabric on Instagram, talks about what she discovered: the garments that helped, the adjustments that mattered, the fabrics she used, and the things she would have loved to have known about earlier. Sheila's hope is that these insights will support others who are sewing for someone navigating cancer treatment, or that you might share this episode with someone who needs it. Cancer data in Australia, Overview of cancer in Australia, 2025 - Australian Institute of Health and Welfare Sewing suggestions to encourage gentle exercise include: Wide brim hats Oversize shirts A totebag A silk pillowcase A cape or poncho Wide brim hat or tubin Loose tank shirt Loose cardigan Sweatshirt in double gauze fabric Soft breathable natural fibres This episode of Sew Organised Style podcast for SewOver50 was both video and audio produced by Maria Theoharous in her sewing room. With permission of Sheila. Sound by Kaneef on Youtube Many thanks for the ongoing monthly support of the podcast's Patreon contributors. Their paid Patreon membership enables me to create these video and audio podcasts for free. You can subscribe to Sew Organised Style podcast, spelt with an s not a z, on all good podcast apps and on YouTube. And yes. If you live in Australia and decide to purchase your own Mimiquin, I'll be your body scanner for Mimiquins UK. Make sure you go back and listen to our free Sewover50 episodes on Sew Organised Style podcast. Tag your makes using @sharesewover50 to be able to find your makes in chronological order on Instagram I look forward to joining you in your sewing room next time. Stay safe everyone. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This Day in Legal History: Lincoln Suspends Habeas CorpusOn April 27, 1861, President Abraham Lincoln authorized military officials to suspend the writ of habeas corpus along the rail lines between Philadelphia and Washington, D.C. The order came in the opening weeks of the Civil War, when Washington was vulnerable, Union troops were moving through hostile territory, and federal officials feared sabotage and rebellion along critical transportation routes.Habeas corpus is one of the oldest protections in Anglo-American law, allowing a detained person to demand that the government justify their imprisonment before a court. By suspending it, Lincoln allowed military authorities to detain certain people without immediately producing them for judicial review. The legal problem was that the Constitution says habeas corpus may be suspended “when in cases of rebellion or invasion the public safety may require it,” but it does not clearly say which branch of government may do the suspending.Lincoln argued that the rebellion created an emergency that required swift executive action. Critics argued that the suspension power belonged to Congress, not the president, because the Suspension Clause appears in Article I, the part of the Constitution dealing mostly with legislative powers. The conflict soon came to a head in Ex parte Merryman, after John Merryman, a Maryland secessionist, was arrested by military authorities and denied ordinary habeas review.Chief Justice Roger Taney, sitting as a circuit judge, ruled that Lincoln had exceeded his constitutional authority and that only Congress could suspend the writ. Lincoln did not comply with Taney's order, maintaining that the survival of the Union justified extraordinary action. Congress later gave statutory support for wartime habeas suspension, but the controversy over Lincoln's initial action has remained central to debates over presidential power, civil liberties, and constitutional government during crisis.The U.S. Supreme Court is set to hear a case involving Cisco Systems and the Alien Tort Statute, focusing on whether U.S. companies can face liability for allegedly helping foreign governments commit human rights abuses. The case comes from Falun Gong practitioners who claim Cisco built surveillance tools for China's “Golden Shield” program that helped officials identify, detain, torture, and persecute members of the religious movement. A federal district court dismissed the case, but the Ninth Circuit revived much of it in 2023, finding the plaintiffs had plausibly alleged that Cisco aided and abetted violations of international law. Cisco argues that the Ninth Circuit improperly expanded the Alien Tort Statute by recognizing aiding-and-abetting liability even though Congress did not expressly create that cause of action. The company says the ATS was originally meant to cover only a narrow set of claims, such as piracy, violations of safe conduct, and harms to ambassadors. Cisco also relies on Supreme Court precedent to argue that courts should not create secondary liability unless Congress clearly authorizes it.The Falun Gong plaintiffs respond that aiding-and-abetting liability has long been part of international law and is especially important when serious abuses require technology, infrastructure, or corporate support. They argue that torture, extrajudicial killing, disappearances, and prolonged arbitrary detention are already recognized as serious international-law violations that can support ATS claims. Business groups and the federal government warn that expanding ATS liability could chill foreign investment and interfere with U.S. foreign relations by forcing American courts to judge the conduct of foreign governments. Supporters of the plaintiffs argue that corporate accountability can discourage companies from profiting from foreign repression and can promote fair competition for businesses that follow human rights standards. The Supreme Court's ruling could shape how much legal risk U.S. companies face when selling technology or services to governments accused of human rights abuses.Justices To Focus On Alien Tort Statute In Cisco Spying CaseThe U.S. Supreme Court is hearing Bayer's attempt to limit or end a large wave of lawsuits over Roundup, the weedkiller Bayer acquired when it bought Monsanto in 2018. The case involves John Durnell, a Missouri man who won a $1.25 million jury verdict after claiming years of Roundup exposure contributed to his non-Hodgkin lymphoma. Bayer argues that federal pesticide law should block state-law failure-to-warn claims because the Environmental Protection Agency has approved Roundup labels without a cancer warning. The company says EPA approval shows the product was not legally “misbranded” and that Bayer could not substantially change the label without agency approval. Durnell's lawyers argue that EPA registration does not make the label immune from challenge and that Missouri warning law mirrors federal requirements rather than adding new ones.The dispute turns on the Federal Insecticide, Fungicide and Rodenticide Act, which regulates pesticide labeling and limits states from imposing requirements that differ from federal law. Bayer says more than 100,000 plaintiffs have brought Roundup-related cancer claims and that a Supreme Court win could largely end the litigation. The company has also proposed a $7.25 billion settlement to resolve many current and future claims, though some pending appeals and excluded claims would remain outside the deal. Agricultural and crop industry groups, along with the Trump administration, support Bayer, while environmental, farmworker, and public health groups support Durnell. Bayer warns that the lawsuits could threaten its ability to keep supplying glyphosate products to farmers. A decision is expected by the end of June.US Supreme Court hears Bayer's fight against Roundup lawsuits | ReutersElon Musk's lawsuit against OpenAI, Sam Altman, Greg Brockman, and Microsoft is headed to trial in federal court in Oakland, California. Musk claims OpenAI betrayed its original nonprofit mission by creating a for-profit structure after he left the board, while using his name and early financial support to build what he calls a profit-driven enterprise. He is reportedly seeking $150 billion in damages, with money going to OpenAI's charitable arm, and also wants OpenAI returned to nonprofit status. OpenAI denies wrongdoing and argues that Musk's real motive is to regain control and help his own AI company, xAI. Microsoft also denies collusion and says its partnership with OpenAI began after Musk had left.The trial is expected to feature testimony from major tech figures, including Musk, Altman, and Microsoft CEO Satya Nadella. Internal documents are likely to play a major role, including diary entries from Brockman that reveal tension inside OpenAI over Musk's influence and the organization's future. Musk's side points to those materials as evidence that OpenAI's leaders became focused on profit rather than the public-benefit mission. OpenAI's side says Musk knew about possible restructuring plans, wanted to be CEO, and later attacked the company after it became successful. The case comes as OpenAI faces heavy competition, major computing costs, and possible IPO plans, while Musk's xAI is also trying to compete in the AI market. The broader fight is not just about money, but about who controls one of the most influential companies in artificial intelligence.Elon Musk's trial against Sam Altman to reveal the ongoing power struggle for OpenAI | ReutersCole Tomas Allen, a 31-year-old California man, is expected to appear in Washington federal court after allegedly trying to breach security at the White House Correspondents' Association Dinner while President Donald Trump was present. Authorities say Allen shot at a U.S. Secret Service agent at a hotel checkpoint before being tackled and arrested. The agent was hit, but a tactical vest stopped the shot, and the agent was later released from the hospital. Formal charges had not yet been filed at the time of the report, but prosecutors said Allen is expected to face charges including assault on a federal officer and using a firearm during a crime of violence. Officials also said more serious charges, including attempted assassination, could still be considered as the investigation continues.Authorities say Allen traveled from California to Washington by train and booked a room at the Washington Hilton, where the dinner was held. They also say he left family members a manifesto referring to himself as the “Friendly Federal Assassin” and discussing plans to target senior Trump administration officials. Acting Attorney General Todd Blanche said Trump may have been among the intended targets. The shooting disrupted the high-profile dinner, forced attendees to take cover, and led security personnel to move senior officials out of the room. Monday's court hearing is expected to be brief, with a judge advising Allen of his rights and prosecutors likely asking that he remain detained. The incident has renewed concerns about security for Trump and other public officials.Suspect in Washington dinner shooting set to appear in court | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

This episode is really special to me.You're going to meet two girls who are both showing us what strength looks like… just in very different ways.First, you'll meet Leahla. Right now, she's going through treatment for Hodgkin's lymphoma. And the way she talks about it? The way she carries herself? It stopped me in my tracks.She's not looking for pity. She's not calling herself a “nebach.” Her words: “We're not nebachs. We're heroes.”And once you hear her explain what that means… you won't forget it.Then you'll meet Sari.After her baby sister spent time in the NICU, Sari realized something powerful: She doesn't just want to learn… she wants to help.She's already thinking about becoming a nurse one day, maybe in oncology, maybe in the NICU… and the way she talks about caring for people, really seeing them, is something every kid (and adult!) needs to hear.So this episode is about two kinds of strength: ✨ The strength to go through something hard ✨ And the strength to step up and help others through it 

Dawn Richard is a proud New Orleans native and a true Renaissance Woman: singer; animator and Adult Swim creative consultant and owner of Papa Ted's vegan food truck in New Orleans.  Dawn went vegan back in 2013, in solidarity with her dad after he received a non-Hodgkin lymphoma diagnosis. She talks about getting naked for PETA, the ethical intentionality behind her food truck and what (not-vegan) food she misses the most but will never eat again.  Then we crack into the history & explore the culture of what is, perhaps, New Orleans' oldest food tradition: crawfish! Food historian Dr Zella Palmer introduces host Rachel Belle to Al Scramuzza, the city's late Crawfish King, and shares her favorite places to experience a crawfish boil in the city.    Become a Cascade PBS member and support public media!     Watch Rachel's Cascade PBS TV show The Nosh with Rachel Belle.   Sign up for Rachel's (free!) biweekly Cascade PBS newsletter for more food musings.   Follow along on Instagram.   Order Rachel's cookbook Open Sesame. 

Gwyneth sits down with Dr. Dawn Mussallem, the chief medical officer for Fountain Life, a longevity clinic powered by AI. They talk about Dawn's incredible health journey–from beating stage four non-Hodgkin lymphoma while in medical school to undergoing a heart transplant at 46–and how that experience now informs her work in the medical field and integrating the powers of AI into health care. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

What happens when you survive cancer… but still feel like giving up?In this powerful episode of Truth Behind the Mike, I sit down with Glen Kirkpatrick—a 2x cancer survivor who faced something even more terrifying than disease: deep depression and suicidal thoughts.Glen shares his raw, unfiltered journey:Being diagnosed with Hodgkin's lymphoma at 30Beating cancer… then watching it come backFalling into severe depression and suicidal ideationThe moment everything nearly endedAnd how God met him in the darkest place imaginableThis is more than a survival story—it's a story of intervention, rescue, and redemption.If you're struggling with:- Depression- Suicidal thoughts- Cancer or chronic illness- Loss of purpose- Or questioning your faithThis conversation is for you.

Mass tort litigation is heating up in 2026 — and this episode breaks down the cases making the biggest impact right now. From a major proposed settlement in the Roundup litigation to growing momentum around PFAS "forever chemical" cases, and ongoing lawsuits tied to Uber safety concerns, this episode gives you a clear, insider view of where things stand. Gregg Goldfarb is joined by Steve Smith of Broughton Partners, to unpack the latest updates, explain what they mean for claimants and attorneys, and highlight why this year could be a turning point for mass tort law. Join Gregg and Steve on "Cut to the Chase" as they discuss: What the proposed Roundup settlement means and why some attorneys are concerned about case values How PFAS contamination became a nationwide legal and public health issue Why 2026 could bring major resolutions across multiple mass tort cases The reality behind Uber lawsuits and ongoing safety concerns How mass tort litigation is evolving for law firms and claimants KEY MOMENTS Uber lawsuits teaser and what's coming in this episode Why 2026 could be a major year for mass torts Roundup settlement update and proposed payout structure Why who you partner with in litigation matters PFAS cases explained: "forever chemicals" and water contamination The scale of PFAS exposure across the U.S. Camp Lejeune updates and what's changing Uber lawsuits: safety concerns and allegations explained How mass tort opportunities are evolving for law firms How to get involved in mass tort litigation Steve Smith is the VP of Business Development at Broughton Partners, where he helps law firms navigate and scale within the mass tort space. With over 20 years of experience in sales, marketing, and business development — including more than a decade focused specifically on legal marketing — Steve has worked closely with many of the nation's top firms on case acquisition, intake strategy, and mass tort growth. Through his work, he specializes in connecting law firms with qualified claimants, vetted litigators, and data-driven strategies that help firms expand into complex litigation while managing risk.   The resources mentioned in this episode are: Learn more about the proposed Roundup settlement, including the tiered payout structure, residential-use claims, and non-Hodgkin's lymphoma cases discussed in this episode. Explore PFAS "forever chemicals" litigation, including firefighter exposure, drinking water contamination, and the push toward a broader resolution of these cases. Learn more about Camp Lejeune water contamination claims and how changes to the statute of limitations have allowed affected individuals to pursue legal action. Watch the film "Falling Waters" referenced in the episode for background on early environmental contamination litigation and how these cases first came to light. Stay informed on Uber-related litigation involving passenger safety concerns, background check practices, and ongoing multidistrict litigation. Learn more about Paraquat litigation and its alleged link to Parkinson's disease, including both MDL and state court case developments.   Contact Steve Smith at Broughton Partners if you are a law firm interested in entering or expanding within the mass tort space: Email: steve@broughtonpartners.com Phone: 954-224-1733 Learn more about Broughton Partners' consortium model, which allows law firms to diversify across multiple mass tort cases with shared resources, vetted partners, and strategic guidance. Want to hear more mass tort updates, and legal issues shaping our communities, affecting everyday people? Subscribe to Cut to the Chase: with Gregg Goldfarb.  

When you're facing a diagnosis, a fear, or a season of waiting, it's easy to feel overwhelmed by the unknown. In today's episode, Tommy Jennings shares a powerful testimony of courage, peace, and unshakable faith as he battles Hodgkin's Lymphoma — a fight he's been in for six years. Tommy's story is raw, honest, and deeply hope‑filled. After exhausting every treatment option, he now lives in the tension of uncertainty — yet his confidence in Jesus has only grown stronger. His words, "Either way it goes, I win," will challenge and inspire you to trust God in your own battles. In this conversation, we talk about: What faith looks like when the prognosis isn't what you hoped for How to cling to God when you're waiting for answers Finding peace in the middle of fear, suffering, and the unknown The hope of Jesus when life doesn't make sense Why Tommy refuses to feel sorry for himself — and how his perspective can reshape your own Whether you're walking through illness, fear, or a difficult season, this episode will remind you that God is near, God is faithful, and God is still writing your story.  Watch on YouTube: Finding Hope in the Unknown: Tommy Jennings' Fight with Cancer Ep. 164 Contact Carol at CarolRoper.org/contact

In this heartfelt and wide-ranging episode, host Bryan reconnects with Jim Bergmann of measureQuick after nearly three years apart. The reunion is anything but ordinary — Jim opens up about a serious battle with non-Hodgkin's B-cell lymphoma that sent him through not one but two rounds of chemotherapy, ultimately requiring a cutting-edge CAR-T cell immunotherapy treatment at the Cleveland Clinic. Jim shares the remarkable medical journey of having his T cells extracted, genetically modified in a Maryland lab, and reintroduced into his body to permanently attack cancer cells. Now past the critical six-month remission milestone, Jim is back, healthy, and more motivated than ever to push the HVAC diagnostics industry forward. From his medical comeback, the conversation transitions naturally into what Jim loves most: the world of HVAC diagnostics and the evolution of measureQuick. After years of defending a per-use pricing model that the market simply didn't embrace, Jim candidly admits the old model wasn't working. With the help of business partner Eric Preston (formerly of TruTech Tools), the team overhauled the software's pricing structure in February — a move that has since driven 90%+ customer retention and accelerated growth significantly. The new focus is squarely on "time to value," streamlining workflows so technicians reach key diagnostic reports faster than ever before. A significant portion of the episode dives into how measureQuick is thoughtfully integrating artificial intelligence. Rather than chasing AI trends, Jim and his team — including AI specialist Ben Reed — took a deliberate approach: identifying the precise areas where AI genuinely helps technicians without creating distractions. The standout use case is label identification, where AI reads equipment labels and auto-populates system profiles. Jim is refreshingly candid about AI's limitations in HVAC diagnostics, explaining that the field variability of real-world systems (varying line set lengths, mismatched equipment, non-standard airflow conditions) makes purely AI-driven diagnostics unreliable. Instead, measureQuick leans on first-principle modeling and non-dimensional mathematics to generate objective, data-driven results. The episode closes with a thought-provoking discussion about the state of the HVAC industry at large. Bryan and Jim tackle the growing influence of private equity consolidation, the persistent problem of technicians skipping probe deployment, the difference between clearing faults and actually fixing them, and the importance of commissioning and retro-commissioning equipment to manufacturer design intent. Throughout it all, the conversation is anchored by a shared belief: that measuring everything — in business and on the job — is the foundation of genuine, lasting improvement. It's a must-listen for any HVAC professional or business owner who wants to understand where the industry is headed. Topics Covered Jim's cancer diagnosis: non-Hodgkin's B-cell lymphoma and the progression from standard chemo to aggressive relapse CAR-T cell immunotherapy explained: how T cells are extracted, genetically modified, and reintroduced to fight cancer permanently Jim's recovery at the Cleveland Clinic and surpassing the critical six-month remission milestone Neurotoxicity as a side effect of CAR-T therapy and what that experience was like The pivot away from measureQuick's per-use pricing model and the dramatic improvement in retention after switching The "time to value" philosophy driving measureQuick's new hybrid workflow interface How measureQuick is integrating AI — and where AI falls short in real-world HVAC diagnostics Label identification as the most practical current AI application in field diagnostics Why AI is highly sycophantic and the danger of relying on subjective, internet-sourced training data for HVAC decisions The power of measureQuick's proprietary measurement data and target zones as a foundation for AI summaries First-principle modeling and non-dimensional mathematics: why brand-agnostic diagnostics work The importance of deploying all nine probes on every air conditioning service call Benchmarking vs. commissioning vs. retro-commissioning: the three layers of equipment assessment Design temperature difference: measuring evaporator and condenser delta-T as engineering benchmarks How ECM motors mask airflow problems — and why that leads to premature motor failure and higher energy costs The two "elephants in the room": incomplete probe deployment and clearing faults without fixing them Why clearing a fault in measureQuick without addressing the root cause is like putting duct tape over a check engine light How poor installation practices in high-growth markets (Florida, Texas, Arizona, Las Vegas) have created widespread system deficiencies The role of private equity in HVAC consolidation and why many PE firms add cost without adding value Why implementing field measurement systems like measureQuick is the missing link for PE-owned and independent shops alike The legacy mode vs. new mode toggle in the upcoming measureQuick update — no forced UI changes for existing users How measureQuick helps newer technicians become productive faster and helps seasoned technicians be more consistent The importance of presenting diagnostic findings to homeowners and helping them understand what the numbers actually mean   Learn more about measureQuick at https://measurequick.com/.  Have a question that you want us to answer on the podcast? Submit your questions at https://www.speakpipe.com/hvacschool. Purchase your tickets or learn more about the 7th Annual HVACR Training Symposium at https://hvacrschool.com/symposium. Subscribe to our podcast on your iPhone or Android. Subscribe to our YouTube channel. Check out our handy calculators here or on the HVAC School Mobile App for Apple and Android.

Despite saying “I believe glyphosate causes cancer” a few weeks ago, RFK Jr quickly pivoted when his boss declared an executive order calling for the ramping up of glyphosate under a 75-year-old defense production act that also happens to give immunity to Bayer, the parent company of Monsanto. MAHA activists immediately went into a frenzy, shocked that their tallow daddy would betray them like this. Mallory DeMille not only coined the term “tallow daddy,” she's also been tracking the civil war that exploded in MAHA after Kennedy said, eh, maybe Roundup ain't so bad after all. Show Notes What to know about glyphosate, the herbicide behind a Trump executive order that's angered MAHA moms Glyphosate Use and Cancer Incidence in the Agricultural Health Study Exposure to glyphosate and risk of non-Hodgkin lymphoma and multiple myeloma: an updated meta-analysis Carcinogenic effects of long-term exposure from prenatal life to glyphosate and glyphosate-based herbicides in Sprague–Dawley rats Learn more about your ad choices. Visit megaphone.fm/adchoices